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GRAPHICAL ABSTRACT 
 
HIGHLIGHTS 
• Blood production is mediated by functionally distinct lineage-biased MPPs 
• MPP subsets are independently produced by HSCs  
• Myeloid-biased MPPs serve as a potent source of myeloid amplification 
• Regeneration occurs at the expense of HSC engraftment and self-renewal activity 
eTOC 
Pietras et al. show that HSCs produce functionally distinct lineage-biased MPPs that work 
together to adapt blood production to hematopoietic demands. Two rare subsets of myeloid-
biased MPP are important for maintaining blood homeostasis at steady state, and serve as a 
potent source of myeloid amplification in regenerative conditions. 
Functionally distinct subsets of lineage-biased multipotent progenitors control 
blood production in normal and regenerative conditions 
Eric M. Pietras1*, Damien Reynaud1*#, Yoon-A Kang1, Daniel Carlin2, Fernando J. Calero-
Nieto3, Andrew D. Leavitt4, Joshua M. Stuart2, Berthold Göttgens3 and Emmanuelle Passegué1§ 
1 The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, 
Department of Medicine, Division of Hematology/Oncology, University of California San 
Francisco, San Francisco, CA 94143, USA.  
2 Department of Biomolecular Engineering and Center for Biomolecular Science and 
Engineering, University of California Santa Cruz, Santa Cruz, CA 94720, USA. 
3 Cambridge University Department of Haematology, Cambridge Institute for Medical Research 
and Wellcome Trust and MRC Cambridge Stem Cell Institute, Hills Road, Cambridge CB2 
0XY, UK. 
4 Departments of Medicine and Laboratory Medicine, University of California San Francisco, 
San Francisco, CA 94143, USA. 
§ Corresponding author: passeguee@stemcell.ucsf.edu 
* Co-first authors 
Footnotes: 
# Current address: Division of Experimental Hematology and Cancer Biology, Cincinnati 
Children's Hospital Medical Center, Cincinnati, OH 45229, USA 
Running Title: Lineage-biased MPPs regulate blood output 
 2 
SUMMARY 
Despite great advances in understanding the mechanisms underlying blood production, 
lineage specification at the level of multipotent progenitors (MPPs) remains poorly understood. 
Here, we show that MPP2 and MPP3 are distinct myeloid-biased MPP subsets that work together 
with lymphoid-primed MPP4 cells to control blood production. We find that all MPPs are 
produced in parallel by hematopoietic stem cells (HSCs), but with different kinetics and at 
variable levels depending on hematopoietic demands. We also show that the normally rare 
myeloid-biased MPPs are transiently overproduced by HSCs in regenerating conditions, hence 
supporting myeloid amplification to rebuild the hematopoietic system. This shift is accompanied 
by a reduction in self-renewal activity in regenerating HSCs and reprogramming of MPP4 fate 
towards the myeloid lineage. Our results support a dynamic model of blood development in 
which HSCs convey lineage specification through independent production of distinct lineage-
biased MPP subsets that, in turn, support lineage expansion and differentiation. 
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INTRODUCTION 
Blood production is a highly regulated process that tailors the output of the myeloid and 
lymphoid lineages based on hematopoietic demands and the needs of the organism (Ema et al., 
2014). Blood development starts with rare self-renewing HSCs that produce a series of 
increasingly more abundant and lineage-committed progenitor cells, ultimately giving rise to all 
types of mature blood cells. While the overall structure of the blood system and its hierarchical 
nature is well established, many questions still remain regarding how HSCs specify lineage fate 
in non self-renewing MPPs prior to the generation of lineage-committed progenitors and the 
separation of the myeloid and lymphoid lineages. 
HSCs are defined functionally by their ability to serially engraft transplanted recipients 
and regenerate the entire blood system. This unique property is used as a direct measurement of 
HSC self-renewal activity, and to identify HSCs based on phenotypic markers. In the mouse, 
HSCs are found in the Lin-/Sca-1+/c-Kit+ (LSK) fraction of the bone marrow (BM), and are 
usually defined as CD150+/CD48- LSK cells (Kiel et al., 2005) although other surface markers 
can be used to enrich for more quiescent and/or functionally distinct subsets including Flk2, 
CD34, EPCR, rhodamine, the other SLAM markers CD229 and CD244, and CD41 (Wilson et 
al., 2008; Kent et al., 2009; Oguro et al., 2013; Yamamoto et al., 2013; Miyawaki et al., 2015). 
Transplantation experiments have shown that markers enriching for the most quiescent and 
metabolically inert HSC subsets will directly favor engraftment and self-renewal activity (Pietras 
et al., 2011; Kohli and Passegué, 2014). Single cell transplantation experiments have further 
demonstrated that even HSCs with identical surface phenotypes are heterogeneous in their 
engraftment behaviors, with different stabilities over time and variable degrees of myeloid vs. 
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lymphoid lineage output (Dykstra et al., 2007; Yamamoto et al., 2013). Several models are 
currently proposed to explain this heterogeneity, including the sequential loss of lineage potential 
in differentiating HSCs (Adolfsson et al., 2005), the existence of long-lived myeloid bypass 
pathways (Yamamoto et al., 2013), and the presence of functionally distinct clones of lineage-
biased HSCs with different biological activities and hard-wired lineage potentials (Muller-
Sieburg et al., 2004; Dykstra et al., 2007). However, it remains unclear whether the behavior of 
transplanted HSCs accurately reflects steady state hematopoiesis and HSC function in native 
conditions. In fact, it is possible that the distinct behaviors exhibited by single transplanted HSCs 
represent reversible activities that span a continuum of surface markers and activation states. The 
identification of MPP1 as a metabolically active subset of HSCs directly supports this idea 
(Cabezas-Wallscheid et al., 2014). Moreover, two exciting lineage tracking studies directly 
marking HSCs in their native environment using either sleeping beauty transposons (Sun et al., 
2014) or Tie2-Cre endogenous labeling (Busch et al., 2015) have recently shown a limited 
contribution of HSCs to steady state hematopoiesis and, conversely, a major role for MPPs and 
lineage-committed progenitors to ongoing blood production. 
MPPs are currently a poorly defined hematopoietic compartment, and the term itself is 
used rather indiscriminately to refer to cells within the LSK fraction that have limited to no 
engraftment ability in transplantation experiments. The best-characterized and most abundant 
MPP subset is defined as Flk2+ LSK cells and is now considered as a fully multipotent but 
lineage-biased population, with low megakaryocyte/erythroid (MegE) and high lymphoid 
potentials (Adolfsson et al., 2005; Forsberg et al., 2006; Boyer et al., 2011; Buza-Vidas et al., 
2011). In fact, the top 25% of the most highly expressing Flk2+ LSK cells have been called 
lymphoid-primed MPPs or LMPPs (Adolfsson et al., 2005). Recently, two other MPP subsets 
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have been described in the Flk2- LSK fraction and termed MPP2 and MPP3, with Flk2+ LSK 
cells re-named MPP4 (Wilson et al., 2008). While preliminary investigations suggest that MPP2 
and MPP3 have myeloid-biased outputs (Cabezas-Wallscheid et al., 2014), little is known about 
their biological function. Here, we directly compared the function of MPP2, MPP3 and MPP4 in 
blood production at steady state and in regenerating conditions following HSC transplantation. 
We propose a model wherein HSCs produce in parallel distinct subsets of lineage-biased MPPs, 
which together coordinate the output of the myeloid and lymphoid lineages in response to 
hematopoietic demands. 
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RESULTS 
Lineage-biased MPP subsets 
Many names and phenotypic definitions are currently used to describe the spectrum of 
MPP subsets present in the mouse LSK BM compartment (Figure 1A). One of the most broadly 
applicable schemes separates the most quiescent HSCs (CD34-/Flk2-/CD150+/CD48- LSK) from 
the more metabolically active MPP1 (CD34+/Flk2-/CD150+/CD48- LSK), and divides MPPs into 
three further distinct subsets: MPP2 (Flk2-/CD150+/CD48+ LSK), MPP3 (Flk2-/CD150-/CD48+ 
LSK) and MPP4 (Flk2+/CD150-/CD48+/- LSK) (Figure 1B) (Wilson et al., 2008; Cabezas-
Wallscheid et al., 2014). Importantly, these populations overlap with other MPP definitions 
based on reporter gene combinations and different surface markers (Arinobu et al., 2007; Akala 
et al., 2008; Oguro et al., 2013). Since our focus was on MPP biology, we did not use CD34 
separation and referred to the combination of HSC and MPP1 as HSCLT. We also included an 
additional sub-population of LSK cells defined as CD34+/Flk2-/CD150-/CD48- LSK (Figure 1B) 
that we named short-term HSCs (HSCST), and referred to the combination of HSCLT and HSCST 
as HSCs. 
Both MPP2 and MPP3 showed low surface expression of Sca-1 compared to HSCs and 
MPP4 and, like MPP4, expressed high levels of CD34 (Figure 1C). However, unlike MPP4, 
they also expressed the HSC markers ESAM (Ooi et al., 2009) and, to various degrees, CD41 
(Figure 1C). In steady state conditions, both MPP2 and MPP3 were as rare as HSCs (Figure 
1D), and were morphologically undistinguishable from other LSK populations (Figure 1E). As 
expected, short-term BrdU incorporation experiments showed higher proliferation rates in MPP2 
and MPP3 than in HSCs, which were in the range of MPP4 (Figure 2A) (Wilson et al., 2008). 
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Liquid culture experiments confirmed similar expansion rates from all three MPP subsets, which 
distinguished them from the long-lived HSCs and growth-restricted common myeloid 
progenitors (CMPs) and granulocyte/macrophage progenitors (GMPs) (Figure 2B). Flow 
cytometry analyses for Mac-1 and FcγR myeloid differentiation markers also demonstrated 
persistence of granulocyte/macrophage (GM) potential in cultured MPP2 and MPP3 compared to 
the transient myeloid output observed with MPP4 (Figure S1A). In clonogenic methylcellulose 
assays, both MPP2 and MPP3 gave rise to all myeloid lineages but with plating efficiency and 
pattern of differentiation distinct from HSCs, MPP4 and myeloid progenitors (Figure 2C). 
Strikingly, MPP3 showed a dominant GM output while MPP2 displayed extensive Meg 
potential, which was confirmed in collagen-based MegaCult assays (Figure 2D). Spleen colony-
forming-unit (CFU-S) assays also indicated similarly strong erythroid potential from both MPP2 
and MPP3, which was intermediate to that of HSCs and MPP4/CMPs (Figure 2E). When 
cultured on OP9/IL-7 to assess B cell potential, both MPP2 and MPP3 generated CD19+ B cells, 
but with kinetics that again were intermediary between HSCLT and MPP4 (Figure S1B). 
Furthermore, single cell analyses revealed ~ 8-fold lower B cell clonogenic potential in MPP2 
and MPP3 compared to MPP4, and a unique ability to produce B/myeloid mix colonies (Figures 
2F and S1C). Similarly, when cultured on OP9-DL1 stromal cells for T cell potential, both 
MPP2 and MPP3 produced CD25+/CD44+ and CD25+/CD44- immature thymocytes with kinetics 
intermediary between HSCLT and MPP4 (Figure S1D). Taken together, these in vitro analyses 
indicate that MPP2 and MPP3 retain full multipotentiality but display specific myeloid biases 
(i.e., Meg for MPP2 and GM for MPP3) analogous to the lymphoid bias exhibited by MPP4. In 
addition, based on surface marker expression, MPP2 could be positioned upstream of Pre-MegE 
and MPP3 upstream of Pre-GM (Figure S1E) (Pronk et al., 2007), thereby establishing a 
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connection between these MPP subsets and myeloid progenitors committed to their dominant 
lineage fate, similar to the link between MPP4 and Flk2-expressing common lymphoid 
progenitors. 
Functional validation 
To further demonstrate the intrinsic myeloid bias of these two MPP subsets, we 
transplanted HSCLT, HSCST, MPP2, MPP3 and MPP4 isolated from β-actin-Gfp mice into sub-
lethally irradiated recipients and followed their multilineage output in peripheral blood (PB) as 
we have previously done (Forsberg et al., 2006) (Figure 3A). These lineage-tracking 
experiments confirmed that MPP2 and MPP3 were both devoid of self-renewal potential 
(Santaguida et al., 2009; Cabezas-Wallscheid et al., 2014) since, like MPP4, they only exhibited 
short-term myeloid reconstitution ability (≤1 months) in contrast to the sustained potential 
displayed by HSCs (Figure 3B). Interestingly, differences in HSCLT and HSCST reconstitution 
activity were only revealed by transplanting a low number of cells (Figure 3B) and tracking the 
persistence of myeloid output for up to 4 months (Figure S2A). In fact, HSCST behaved similarly 
to the previously described intermediate-term HSCs (ITRC) (Benveniste et al., 2010). 
Importantly, these lineage-tracking experiments directly showed the multipotent nature of MPP2 
and MPP3, and their ability to generate low levels of B and T cells in vivo (Figure S2B). They 
also highlighted the considerable but transient ability of MPP2 to produce platelets (Figures 3B 
and S2C), and the extensive GM potential of both MPP2 and MPP3, which were able to 
maintain production of mature myeloid cells for two weeks longer than MPP4 (Figure 3C). 
Taken together, these in vivo experiments confirm that MPP2 and MPP3 are two myeloid-biased 
MPP subsets that are functionally distinct from the lymphoid-primed MPP4. 
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Molecular validation 
To understand how MPP2 and MPP3 fit into the hematopoietic continuum, we conducted 
genome-wide microarray analyses. Hierarchical clustering based on gene signatures derived 
from the 1000 most highly differentially expressed genes in HSCLT and GM lineage-committed 
cells (Figures S3A, S3B, and Table S1), divided the hematopoietic hierarchy into three main 
groups: (1) highly immature HSCLT and HSCST; (2) multipotent progenitors including MPP2, 
MPP3, MPP4 and early myeloid-committed CMPs; and (3) GM lineage-committed cells 
including GMPs, Gr precursors (Pre Gr) and Gr (Figure 4A). Interestingly, principal component 
(PC) and gene ontology (GO) analyses identified inflammation genes as main drivers of PC1, 
which set apart the entire GM-committed myeloid differentiation axis, while cell cycle genes 
drove PC2, which segregated HSCST from HSCLT, and metabolism genes PC3, which separated 
MPP2 and MPP3 from MPP4 (Figure 4B, S3C and Table S2). Moreover, GO analyses 
performed on gene signatures representing the 1000 most highly differentially expressed genes in 
each MPP relative to the other two underscored their unique molecular features (Figures 4C, 4D 
and Table S3). As expected, the MPP4 signature was enriched in lymphoid differentiation 
genes, while MPP3 signature was enriched for myeloid differentiation genes and MPP2 signature 
for genes related to hemostasis. Consistently, MPP2 showed features of an active MegE 
transcription program, with high expression levels of Gfi1b, Gata1 and Fog1 (Figure S3D). 
These distinct gene expression signatures allowed recognition of MPP2, MPP3 and MPP4 in 
other published gene expression datasets (Table S4). Taken together, these molecular studies 
corroborate our functional analyses by positioning the rare myeloid-biased MPP2 and MPP3 
together with the more abundant lymphoid-primed MPP4 in a multipotent compartment located 
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downstream of HSCs and upstream of the already lineage-committed myeloid and lymphoid 
progenitors. 
Hierarchical organization 
To confirm the hierarchy between MPP2, MPP3 and MPP4, we first performed short-
term in vitro differentiation experiments, and followed changes in early stem and progenitor 
surface marker expression by flow cytometry (Figure 5A and S4A). While robust c-Kit and Sca-
1 expression allowed tracking of LSK differentiation, the lack of Flk2 induction in vitro, or its 
quick down-regulation following exposure to Flt-3 ligand, did not permit the separation of newly 
generated MPP3 and MPP4. In both HSCLT and HSCST cultures, we observed a persistent LSK 
compartment, which first produced MPP2 and then MPP3/4 (Figure 5A). In contrast, in MPP 
cultures, the LSK compartment quickly differentiated into c-Kit+/Sca-1- myeloid progenitors and 
c-Kit-/Sca-1- mature myeloid cells, with the few remaining LSK cells preserving their initial 
identity despite some fluctuation in marker expression (Figure S4A). While these in vitro results 
establish that MPP2 is the first MPP subset produced by differentiating HSCs, they do not 
distinguish whether MPP2 then make MPP3/4, or whether the other MPP subsets are directly 
generated from HSCs but with slower kinetics. To further clarify this relationship, we took 
advantage of mice lacking the thrombopoietin receptor (Mpl) gene (Gurney et al., 1994) to 
determine how defects in platelet production could affect the genesis of the different MPP 
subsets (Figure 5B). We confirmed the major decrease in HSCLT and HSCST in Mpl-/- mice (Qian 
et al., 2007), and found a consistent ~ 2-fold reduction in the numbers of MPP2 and all lineage-
committed progenitors with Meg activity including Pre-MegE, MkP and CMP (Figure 5B and 
S4B). In sharp contrast, the numbers of MPP3, MPP4 and other progenitors devoid of Meg 
 11 
activity remained unchanged. These results highlight the key contribution of the Meg-biased 
MPP2 to megakaryopoiesis, and suggest that MPP3 and MPP4 are produced independently from 
MPP2 by HSCLT. Finally, we transplanted MPP2, MPP3 and MPP4 isolated from wild type mice 
into sub-lethally irradiated recipients, to evaluate their ability to regenerate other MPP subsets 
shortly after transplantation (Figure 5C). However, despite injecting high cell numbers, we were 
unable to detect production of donor-derived LSK cells in BM from any MPP subsets, while in 
the same conditions HSCLT regenerated a robust LSK population within 14 days post-
transplantation (Figure 5C and S4C). In contrast, after 10 days, we observed strong production 
of donor-derived GMPs from all MPP subsets, which persisted 14 days after transplantation for 
MPP2 and MPP3, but not for MPP4, which, by then, was mostly producing lymphoid-derived 
progeny (Figure S4D). These results confirm the enhanced production of GMPs by myeloid-
biased MPP2 and MPP3, and demonstrate that no MPPs are able to generate other MPPs in vivo. 
Taken together, these experiments establish a hierarchy where HSCs independently generate all 
three types of lineage-biased MPPs, but with faster production of Meg-biased MPP2 over GM-
biased MPP3 and lymphoid-primed MPP4. 
Molecular priming at steady state 
To gain insights into the molecular pathways controlling the production of these different 
MPP subsets, we used a custom-made Fluidigm dynamic PCR array platform to analyze the 
expression of 57 genes in pools of 100 HSCLT, MPP2, MPP3 and MPP4 (Figure 5D). 
Importantly, we detected the expected changes in expression of the surface markers Slamf1 
(CD150), Cd48 and Flt3 (Flk2) that define the identity of these populations (Figure S5A). 
Overall, we found a significant reduction in expression of self-renewal genes in MPPs compared 
 12 
to HSCLT, which was more pronounced in MPP3 than in MPP4 (Figure 5D), and was confirmed 
at the protein level using cells isolated from Bmi1-eGFP reporter mice (Figure S5B) (Hosen et 
al., 2007). We also documented the Meg poising of MPP2, with maintenance of Gata2 
expression to levels similar to HSCLT, and the lymphoid priming of MPP4, with induction of 
Rag1 and higher expression of Ikzf1 (Ikaros) compared to HSCLT and other MPP subsets (Figure 
5D). In addition, both MPP3 and MPP4 showed clear evidence of GM poising compared to 
HSCLT and MPP2, with induction of Cebpa, Irf8 and Sfpi1 (Pu.1) gene expression and protein 
levels as measured in cells isolated from Pu.1-eYFP reporter mice (Figure 5D and S5B). 
Consistent with their active cell cycle status, all MPPs displayed higher expression levels of 
specific G1-to-S and G2-to-M phase cyclin/CDK complex genes compared to HSCLT, and a 
major down-regulation of the quiescence-enforcer Cdkn1c (p57) (Figure S5C). All MPPs also 
showed elevated expression levels of some DNA repair pathway components, especially Rad51 
and Rpa1 (Figure S5C). Moreover, we performed single cell analyses with the same Fluidigm 
platform, and investigated the 49 most robustly expressed genes using PC analyses and t-
distributed stochastic neighbor embedding (tSNE) to pinpoint the key molecular drivers 
segregating these different populations (Figure 5E and S5D). As expected, Cd48, Slamf1 and 
Flt3 were all important for PC1 separation. In addition, Cebpa, Irf8, Ccne1/2 (cyclin E1 and E2) 
and Rad51 emerged as important drivers for both PC1 and PC2 separation, which together with 
Slamf1 distinguished MPP2 and MPP3 from each other, and separated them from HSCLT and 
MPP4. Collectively, these analyses demonstrate that, at steady state, all three MPP subsets are 
part of an actively proliferating continuum of differentiation with molecular priming towards 
their respective lineage biases and, in the case of the most abundant MPP4, persistence of a 
significant GM poising alongside its lymphoid priming. 
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Contribution to blood regeneration  
To understand how each MPP subset emerges from HSCs and contributes to blood 
regeneration, we injected CD45.2 donor HSCLT into sub-lethally irradiated CD45.1 congenic 
recipients and followed the production of donor-derived BM populations at 2 and 3 weeks post-
transplantation (Figure 6A). Strikingly, at 2 weeks, both MPP2 and MPP3 were massively 
expanded and accounted for most of the reforming LSK compartment, with HSCLT and HSCST 
being exceedingly rare and MPP4 just starting to be generated (Figure 6B and 6C). By 3 weeks, 
this process began to revert, with MPP2 and MPP3 contracting toward their steady state levels as 
HSCLT and MPP4 expanded. In addition, at 2 weeks, all donor-derived BM cells were essentially 
myeloid, while by 3 weeks, lymphopoiesis had recovered, with a BM lineage composition 
becoming similar to steady state levels (Figure 6C and S5E). Consistently, we observed a 
transient expansion of GMPs at 2 weeks, with kinetics matching the initial burst of MPP2/MPP3 
expansion and myeloid cell production (Figure 6C). These results indicate that regenerating 
HSCs first produce myeloid-biased MPPs to quickly establish myeloid output, followed by 
lymphoid-primed MPP4 to rebuild the lymphoid lineages. Functional assessment in 
methylcellulose showed similar plating efficiency and overall lineage distribution between newly 
produced MPP subsets at 2 and 3 weeks, compared to steady state (Figure 6D). In contrast, 
regenerating HSCLT at 2 weeks displayed profoundly impaired differentiation potential in vitro, 
which was in large part recovered by 3 weeks (Figure 6D).  
We also performed Fluidigm gene expression analyses on pools of 100 donor-derived 
cells re-isolated at 2 and 3 weeks post-transplantation to gain a molecular understanding of this 
regeneration process (Figure 6E and S6). PC analyses indicated that regenerating HSCLT and 
newly generated MPP2 preserved their overall molecular identity, while MPP3 and MPP4 
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showed greater dispersion, mainly reflecting more pronounced changes in expression levels of 
certain lineage commitment genes (Figure 6E). In particular, Meg/E lineage determinants were 
significantly downregulated in MPP3 and MPP4, while being preserved in both HSCLT and 
MPP2 (Figure S6). In addition, MPP4 showed changes in both lymphoid lineage determinants, 
with transient up-regulation of Rag1 and Ikzf1 at 2 weeks, and GM lineage determinants. In fact, 
we discerned two reciprocal patterns of changes in myeloid commitment genes in regenerating 
HSCLT and newly produced MPP4. At 2 weeks, both populations showed increased expression 
of Pu.1 and Runx1 and decreased expression of Cebpa and Irf8, which completely reversed at 3 
weeks (Figure S6). In contrast, newly produced MPP2 and MPP3 displayed limited changes in 
GM lineage determinants aside from increased expression of Irf8 at 3 weeks and fluctuations in 
Hoxa9 expression. These results show that MPP4 undergo a significant molecular 
reprogramming during regeneration, while newly produced MPP2 and MPP3 are able to 
maintain a strong Meg and GM potential, respectively, hence highlighting the stability of their 
intrinsic lineage priming. Altogether, they identify MPP2/MPP3 as a compartment of myeloid 
amplification emerging rapidly from regenerating HSCLT, and suggest that the molecular 
reprogramming of MPP4 also likely contributes to the initial burst of myeloid cell production 
Functional reprogramming in regenerating HSCs  
To further investigate the changes in self-renewal activity occurring in regenerating 
HSCLT, we re-transplanted donor-derived HSCLT isolated at 2 and 3 weeks post-transplantation 
into lethally-irradiated secondary recipients, and compared their engraftment to freshly isolated 
control HSCLT (Figure 7A). Strikingly, both 2 and 3 week regenerating HSCLT showed a nearly 
complete lack of reconstitution activity in PB output and BM engraftment compared to control 
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HSCLT (Figures 7B, 7C, and S7A). Limit dilution analyses (LDA) performed with 
unfractionated BM cells directly confirmed the impaired engraftment ability of 2 week 
regenerating HSCLT independently of surface markers (Figures 7D and S7B). Both 2 and 3 
week regenerating HSCLT also clearly displayed an activated status, characterized by decreased 
expression of the quiescence-enforcing transcription factors Foxo3a and Egr1, increased 
expression of Slamf1 and the MPP markers Cd48 and Flt3, and induction of the cell cycle 
machinery with increased expression of G2-to-M phase cyclin/CDK complex genes (Figure 7E). 
Short-term in vivo EdU incorporation experiments directly confirmed the highly proliferative 
status of 2 week regenerating HSCLT, which had essentially returned to steady state levels by 3 
weeks (Figure 7F). In fact, by 4 weeks post-transplantation, donor-derived HSCLT had also 
restored normal engraftment ability in vivo and plating activity in methylcellulose (Figure S7C 
and S7D). Finally, cytokine array analyses showed minimal perturbation in cytokine levels 
(including M-CSF and IL-1) except for increased IL-6 production in the BM cavity of 
transplanted mice (Figure 7G, S7E and data not shown). Taken together, these results 
demonstrate that regenerating HSCLT temporarily lose their self-renewal activity as they 
overproduce myeloid-biased MPPs, and only recover their normal engraftment when blood 
homeostasis and adequate production of lymphoid-primed MPP4 are restored.  
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DISCUSSION 
Here, we show that the MPP compartment is composed of at least two distinct subsets of 
myeloid-biased MPPs (i.e., MPP2 and MPP3), which work together with lymphoid-primed 
MPP4 to regulate blood production. We find that all three subsets of lineage-biased MPPs are 
independently produced by HSCs, but with different kinetics and at varying levels depending on 
hematopoietic demands. We demonstrate that myeloid-biased MPPs are important for 
maintaining blood homeostasis at steady state, and for rebuilding the myeloid lineages in 
regenerative conditions. Taken together, our results support a model of blood development that 
highlights the key role of the MPP compartment, and place its various lineage-biased subsets at 
the center stage of lineage specification. They also support the idea that the HSC compartment is 
functionally plastic, with HSCs committed to differentiation to support blood regeneration 
temporarily losing their engraftment ability. This updated scheme has important implications for 
understanding HSC self-renewal and blood production in various physiological contexts. 
Competing models of blood development 
HSCs are extremely efficient at sustaining long-term multilineage hematopoietic 
reconstitution in vivo, and are the only blood cells amenable to single cell transplantation assays. 
In contrast, the functional characterization of multipotent or lineage-committed progenitors 
remains challenging due to their low yield and transient output in transplantation assays, which 
preclude most clonal analyses except for the recent attempt at lentiviral barcoding of MPP4 
(Naik et al., 2013). As a consequence, current models of blood development place significantly 
more emphasis on HSC function as measured by transplantation rather than on the activity of 
non-self-renewing MPPs to explain lineage specification. In the “clonal composition” model, the 
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distinct patterns of blood reconstitution in single cell transplantation assays are explained by 
selection of particular HSC clones (Copley et al., 2012), and the myeloid bias associated with old 
age by a shift in clonal dominance with over-representation of myeloid-biased HSCs (Beerman 
et al., 2010). Consistent with this idea, myeloid-biased HSCs have been prospectively identified 
based on Hoechst dye exclusion (Challen et al., 2010) or high CD150 expression (Morita et al., 
2010). Both the “graded differentiation” and “myeloid bypass” models directly argue against the 
existence of true MPPs and propose instead either a gradual loss of lineage potential with 
differentiation, starting with loss of Meg potential at the HSC stage (Adolfsson et al., 2005) and 
dendritic cell (DC) potential at the MPP4 stage (Naik et al., 2013), or the existence of long-lived 
myeloid-restricted repopulating progenitors that produce myeloid cells independently from other 
lineages (Yamamoto et al., 2013). However, all these models are interpretations of reconstitution 
patterns in transplanted mice that are unlikely to reflect HSC function and lineage specification 
in native conditions as directly suggested by two recent lineage tracking studies, which both 
showed limited contribution of HSCs to ongoing hematopoiesis (Sun et al., 2014; Busch et al., 
2015). It is also clear that engraftment and quiescence are intrinsically connected, and that more 
metabolically active MPP1 are less engrafting than quiescent HSCs (Cabezas-Wallscheid et al., 
2014). However, it remains unclear whether MPP1 are truly separable from HSCs or whether 
they represents a reversible stage of HSC activation. This unfortunately cannot be directly tested 
using transplantation approaches. 
To reconcile these observations, we propose a “dynamic model” of blood development in 
which the HSC compartment is, in fact, composed of distinct subsets of quiescent, activated and 
lineage-primed HSCs that represent a continuum of likely reversible states and encompass the 
currently described HSCLT (HSC/MPP1) and HSCST/ITRC populations. In turn, this plastic HSC 
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compartment conveys lineage specification through the independent production of distinct 
subsets of lineage-biased MPPs, in proportions that are based on hematopoietic demands (Figure 
7H). This differs substantially from the prevailing views that consider HSCs solely as an 
engrafting population rather than a continuum of functional activity, and MPPs as a single linear 
progression of differentiation rather than parallel pathways that independently control the output 
of the myeloid and lymphoid lineages. The capacity of HSCs to independently produce specific 
subsets of lineage-biased MPPs is likely to contribute to the clonal heterogeneity observed upon 
single cell transplantations. Hence, myeloid-biased HSCs and long-lived myeloid-restricted 
repopulating progenitors could reflect the reconstitution pattern of HSCs that are primed to 
produce myeloid-biased MPP2 and MPP3, with balanced HSCs reflecting the behavior of 
uncommitted HSCs and lymphoid-biased HSCs of HSCs that are poised to produce lymphoid-
primed MPP4. 
Parallel MPP compartments 
Our results considerably expand on the functional characterization of the MPP 
compartment. We show that while fully multipotent in permissive culture conditions, both 
myeloid-biased MPPs display specific lineage preferences (i.e., Meg for MPP2 and GM for 
MPP3). We confirm these biases at the molecular level, with lineage priming reflective of the 
dominant blood output for each MPP subset, but otherwise only modest differences in their 
global transcriptional networks as expected for multipotent progenitors. In the case of the 
lymphoid-primed MPP4, it is also likely that their strong GM poising directly contributes to their 
ability to produce myeloid cells at steady state and to be quickly reprogrammed towards 
exclusive myeloid output in regenerative conditions. We validate these lineage biases in vivo by 
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showing that MPP2 and MPP3 are more efficient at producing GMPs than MPP4, and by 
establishing the importance of MPP2 for megakaryopoiesis using Mpl-/- mice. Moreover, we 
show that HSCs independently produce all MPP subsets, but at different levels and with different 
kinetics as exemplified by the delayed emergence of the lymphoid-primed MPP4 in regenerative 
conditions and the faster production of the Meg-biased MPP2 in vitro. This is interesting in the 
context of the strong Meg potential described for HSCs further purified with Von Willebrand 
factor (Sanjuan-Pla et al., 2013), which could directly reflect in vivo enrichment of HSCs that are 
primed to produce Meg-biased MPP2. Our results also indicate that Flk2- myeloid-biased MPPs 
are produced independently of Flk2+ MPP4, which contradicts recent fate-mapping results 
suggesting that all blood cells are derived from Flk2-expressing progenitors (Boyer et al., 2011). 
However, since MPP2 and MPP3 both express Flk2 mRNA at low levels at steady state and at 
increasing levels during regeneration, it is possible that the transgenic Flk2-Cre used in these 
experiments is activated in these MPP subsets despite their lack of Flk2 surface protein 
expression. Another possibility is that the early window during which MPP2 and MPP3 rebuild 
the myeloid lineage, before re-establishment of homeostasis and the dominant contribution of 
Flk2+ MPP4, has been missed in this study. It will therefore be important to use additional in 
vivo tracking approaches, such as those recently published in native conditions (Sun et al., 2014; 
Busch et al., 2015), to precisely map the differentiation paths of these MPP subsets. 
Molecular reprogramming in regenerative conditions 
Consistent with their lineage biases and specific roles in myeloid cell production, we 
show that the lineage programming of MPP2 and MPP3 remains largely unchanged during 
regeneration. In contrast, HSCs and MPP4 show transient reprogramming of their lineage fate, 
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with altered expression of similar myeloid lineage genes during blood regeneration. This is 
characterized by downregulation of Cebpa/Irf8 and concomitant upregulation of Runx1/Pu.1, 
suggesting that the rebalancing of these two sets of transcription factors plays an important role 
in priming myeloid lineage output in regenerative conditions. Indeed, C/EBPα is dispensable for 
regenerative ‘emergency’ granulopoiesis (Hirai et al., 2006), and its downregulation may 
represent a mechanism to activate HSC proliferation (Ye et al., 2013). Recent evidence also 
suggests that elevated levels of Pu.1, a direct target of Runx1, are crucial for promoting rapid 
myeloid differentiation in HSCs (Mossadegh-Keller et al., 2013). These reciprocal changes could 
therefore enforce HSC proliferation and transiently favor HSC differentiation along a myeloid-
biased MPP pathway, with decreased expression of Irf8 eventually limiting monocyte/DC 
specification in the context of elevated Pu.1 activity (Tamura and Ozato, 2002). The transient 
induction of this program in MPP4 could directly enforce myeloid output in a population that, 
despite its GM priming, is also beginning to upregulate key lymphoid differentiation genes. The 
increased IL-6 levels detected in the BM cavity of transplanted mice could be part of this 
mechanism, as IL-6 is known to reprogram MPP4 away from lymphoid differentiation and to 
amplify myeloid differentiation (Reynaud et al., 2011).  
Implications for blood production 
Our results support the idea that myeloid-biased MPPs serve as a transient compartment 
of myeloid expansion that can be rapidly activated by HSCs to ensure appropriate production of 
myeloid cells (Figure 7H). They also demonstrate that regenerating HSCs temporarily lose self-
renewal activity as they overproduce myeloid-biased MPPs and rebuild the blood system, a 
phenotype perhaps linked to their increased cell cycle activity, activated metabolic status and/or 
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myeloid priming (Kohli and Passegué, 2014). This finding raises further caution about defining 
HSC identity solely based on transplantation experiments, as regenerating HSCs do not perform 
well in this assay despite being fully capable of maintaining blood production over time. It also 
raises the interesting possibility that increased CD150 expression observed in both poorly 
engrafting myeloid-biased HSC clones (Morita et al., 2010; Beerman et al., 2010) and 
regenerating HSCs is linked to the production of myeloid-biased MPPs, and is essentially a 
reflection of their activated/primed status. It will now be interesting to explore whether 
differential production of lineage-biased MPPs by HSCs could account for other long-lasting 
changes in blood production such as the predominant lymphoid/GM output of fetal 
hematopoiesis (Kawamoto, 2006), the GM skewing, immunosenescence and anemia of the old 
blood system (Geiger and Rudolph, 2009), or the aberrant overproduction of different myeloid 
lineages in hematological malignancies (Tefferi and Gilliland, 2007). It will also be exciting to 
determine whether similar populations of myeloid-biased MPPs exist in humans. In addition, one 
of the main complications of anti-cancer therapies or BM transplantation protocols is their 
deleterious effect on the blood system, leading to prolonged neutropenia and increased risk of 
infections. It will therefore be compelling to test whether HSC differentiation pathways can be 
manipulated to favor production of specific lineage-biased MPPs, and thereby optimize blood 
recovery following hematopoietic injury or rebalance lineage output in an aging or deregulated 
blood system.  
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EXPERIMENTAL PROCEDURES  
Mice and flow cytometry 
Six- to 8-week-old CD45.2 C57Bl/6 wild type or β-actin-Gfp (Forsberg et al., 2006) mice were 
used as donor for cell isolation, and 8-12 week old CD45.1 C57Bl/6-Boy/J wild type mice as 
recipients for cell transplantation. Transplanted mice were kept on antibiotic-containing water for 
4 weeks. All mice were maintained at UCSF in accordance with IACUC approved protocols. 
Staining and enrichment procedures for flow cytometry were performed as previously described 
(Santaguida et al., 2009; Reynaud et al., 2011). Cells were sorted on a FACS ARIAII and 
analyzed on an LSRII (Becton Dickinson) upon PI exclusion of dead cells. Each population was 
double sorted to ensure maximum purity. 
In vitro analyses 
Proliferation, BrdU incorporation, differentiation and OP9/OP9-DL1 co-culture experiments, 
Microarray and Fluidigm analyses were performed as described in the Extended Experimental 
Procedures. Three to five independent biological replicates were used for each population.  
Methylcellulose and MegaCult assays were performed according to the manufacturer’s protocols 
(Stem Cell Technologies). 
In vivo analyses 
Transplantations, lineage tracking and spleen colony-forming unit (CFU-S) assay were 
performed as previously described (Forsberg et al., 2006; Reynaud et al., 2011). Congenic 
recipient mice (CD45.1) were either lethally (1100 rad, split dose 3h apart) or sub-lethally (950 
rad, split dose 3h apart) irradiated. Purified donor cells were injected into the retro-orbital plexus 
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and hematopoietic reconstitution was monitored over time in the peripheral blood based on 
CD45.2 or GFP expression. EdU incorporation experiments and cytokine analyses were 
performed according to the manufacturer’s protocols (Life Technologies). 
Statistics 
All data are expressed as mean ± standard deviation (SD) or standard error of the mean (SEM) as 
indicated. P values were generated using unpaired Student’s t-test or a Mann-Whitney u-test 
(Fluidigm), and considered significant when ≤ 0.05. N indicates the numbers of independent 
experiments performed. 
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FIGURE LEGENDS 
Figure 1. Re-investigating MPP subsets. 
(A) Table showing overlap of MPP subsets with previously published definitions. 
(B) Representative gating strategy used to identify and isolate HSCLT, HSCST, MPP2, MPP3 and 
MPP4 based on expression of Flk2, CD48 and CD150 in BM LSK.  
(C) Representative histograms of Sca-1, CD34, ESAM and CD41 expression in the indicated 
LSK subsets. 
(D) Average percentage in BM LSK and absolute numbers of each population (8 mice/group). 
(E) Wright-Giemsa staining of the indicated LSK subsets. 
Results are expressed as mean ± SD. 
Figure 2. Co-existence of functionally distinct MPP subsets. 
(A) Proliferation rates. Cells were pulsed for 1h with BrdU before analysis (n ≥ 3). 
(B) Expansion in liquid culture. Cells were counted every other day (n = 2). 
(C) Methylcellulose clonogenic assays and pictures of representative colonies. Single cells were 
used to measure plating efficiency and colony forming unit (CFU) activity (n ≥ 3). 
(D) Meg differentiation potential in collagen-based MegaCult assays (n = 2). mCFU-Meg: small 
mature colony of ≤ 6 Meg; eCFU-Meg: large early colony of ≥ 6 Meg. 
(E) CFU-S assays. Representative photograph of spleen colonies obtained after transplantation of 
the indicated populations in lethally irradiated mice (n = 2). CFU-S frequency is given at day12. 
(F) Clonogenic B-cell differentiation potential on OP9/IL-7 stromal cells. Single, 10 and 50 cells 
were grown for 16 days and analyzed by flow cytometry for production of CD19+ B cells (10-34 
wells/cell dose).  
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Results are expressed as mean ± SEM; °p < 0.05, • p < 0.01, * p < 0.001. 
See also Figure S1. 
Figure 3. Specific lineage biases in MPP subsets. 
(A) Experimental scheme for the in vivo lineage tracking experiments. GFP+ populations were 
transplanted into sub-lethally irradiated recipients and followed over time for their reconstitution 
activity and lineage potential in PB. 
(B) Platelet chimerism following transplantation of 2,000 (upper graphs) or 500 (lower graphs) 
cells of the indicated donor GFP+ population. Each line represents individual mice (2-4/group). 
(C) Nucleated cell chimerism (upper graphs) and percent of donor-derived Mac1+ myeloid cells 
(lower graphs) following transplantation of 2,000 cells of the indicated donor GFP+ population. 
Each line represents individual mice (2-4/group). 
See also Figure S2. 
Figure 4. Molecular biases in MPP subsets.  
(A) Hierarchical clustering analysis based on the 1000 most highly expressed genes in HSCLT 
and GM lineage-committed cells (GMP, Gr precursors: pre Gr; Gr). * Indicates one MPP4 
sample clustering independently. 
(B) Principal component (PC) analysis of the microarray results shown in (A). Axis labels 
indicate the primary gene signature driving each PC separation. 
(C) Individual gene signatures representing the 1000 most highly expressed genes in MPP2, 
MPP3 and MPP4 relative to the other two populations. 
(D) Gene ontology (GO) analyses of the gene signatures shown in (C). 
See also Figure S3 and Table S1, S2, S3, S4. 
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Figure 5. Hierarchical organization and molecular priming.  
(A) Differentiation in vitro. Representative FACS plots showing HSCLT and HSCST 
differentiation kinetics in myeloid conditions (n = 2). 
(B) Size of the indicated BM populations in Mpl-/- and littermate control mice (3 mice/group). 
(C) Differentiation in vivo. Representative FACS plots of LSK and myeloid progenitor output 10 
days following transplantation of 5,000 cells of the indicated donor population (3 mice/group).  
(D) Fluidigm gene expression analyses at steady state. Results are expressed as mean (bar) and 
individual fold differences compared to HSCLT (8-12 pools of 100 cells /population; nd: not 
detectable). 
(E) t-distributed stochastic neighbor embedding (tSNE) analysis of Fluidigm gene expression 
data acquired from single cells (30-58 cells/population). 
Results are expressed as mean ± SD; °p < 0.05, •p < 0.01, *p < 0.001. 
See also Figures S4 and S5. 
Figure 6. Contribution to blood regeneration. 
(A) Experimental scheme for in vivo blood regeneration experiments. Donor HSCLT were 
transplanted into sub-lethally irradiated congenic recipients (2,000 HSCLT/mouse) and 
regeneration of donor BM subsets was followed at 2 and 3 weeks post-transplantation and 
compared to steady state control (Ctrl) mice. 
(B) Representative FACS plots of regenerating BM subsets. 
(C) Frequency of the indicated BM subsets (6-10 mice/group). 
(D) Methylcellulose clonogenic assays for the indicated populations (n = 1-4) 
(E) PC analysis of Fluidigm gene expression data from the indicated populations (8-12 pools of 
100 cells/condition). 
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Results are expressed as mean ± SD or SEM (D); °p < 0.05, •p < 0.01, *p < 0.001. 
See also Figure S5, S6. 
Figure 7. Myeloid-biased MPPs are a transient compartment of myeloid amplification. 
(A) Experimental scheme for re-transplantation of regenerating HSCLT. Donor CD45.2 HSCLT 
isolated from primary recipients at 2 and 3 weeks post-transplantation or from Ctrl mice were 
injected into lethally irradiated secondary CD45.1 recipients (100 HSCLT/mouse) together with 
3x105 Sca-1-depleted CD45.1 BM cells (4-13 mice/group). 
(B) Engraftment over time in PB. 
(C) Engraftment in BM HSCLT at 16 weeks post-transplantation. 
(D) Limit dilution analyses (LDA) of Ctrl (black) and 2 weeks post-transplantation (red) BM 
cells. Dotted lines represent confidence intervals and values the estimated HSC frequency. 
(E) Fluidigm gene expression analyses of key self-renewal determinant, surface marker and cell 
cycle genes in regenerating HSCLT at 2 and 3 weeks post-transplantation. Results are expressed 
as mean (bar) and individual fold compared to steady state Ctrl HSCLT (8-12 pools of 100 
cells/condition). 
(F) Proliferation rates in mice pulsed for 1h with EdU (n = 1-3). 
(G) IL-1 and IL-6 levels in BM fluids (5 mice/group). 
(H) Revised model of blood production at steady state and in regenerating conditions. 
Results are expressed as mean ± SD or SEM (F); °p < 0.05, •p < 0.01, *p < 0.001. 
See also Figure S7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S1, Functional characterization of BM LSK subsets, related to Figure 2. (A) Myeloid 
differentiation potential in liquid culture. Representative FACS plots showing the kinetics of 
FcγR and Mac-1 acquisition in the indicated populations (n ≥ 2). (B) B cell differentiation on 
OP9/IL-7 stromal cells. Representative FACS plots showing the kinetics of CD19+ B-cell and 
Mac-1+ myeloid (M) cells differentiation over time. Results are representative of 4 independent 
experiments. (C) Representative FACS plots showing unique B and mix B/M output from single 
MPP3 and MPP4 cultured for 16 days on OP9/IL-7 stromal cells. The frequency for each output 
is indicated. (D) T cell differentiation on OP9-DL1 stromal cells. Representative FACS plots 
showing the kinetics of CD25 and CD44 acquisition in the indicated populations. Results are 
representative of 4 independent experiments. (E) Representative FACS plots showing that MPP2 
and MPP3 are phenotypically related to Pre-MegE and Pre-GM progenitors, respectively. 
  
Figure S2, In vivo reconstitution assays, related to Figure 3. (A) CD45.2 HSCLT or HSCST 
were transplanted into lethally irradiated CD45.1 recipients (50 cells/mice) together with 3x105 
Sca-1-depleted CD45.1 BM cells. The table and FACS plots illustrate engraftment and 
percentage of CD45.2+ donor-derived myeloid (Mac1+) and lymphoid (B220+/CD3+) cells in the 
peripheral blood at 4 and 16 weeks post-transplantation. Results are expressed as mean ± SD. (B) 
Representative FACS plots showing examples of nucleated myeloid cells (Mac-1+/Gr-1+), B 
cells (B220+) and T cells (CD3+) produced by the indicated donor GFP+ populations 27 days 
post-transplantation. (C) Representative FACS plots showing examples of platelets (Ter-119-/Gr-
1-/CD61+) produced by the indicated donor GFP+ populations 20 days post-transplantation. 
  
  
Figure S3, Molecular characteristics of lineage-biased MPP subsets, related to Figure 4. (A) 
Individual gene signatures representing the 1000 most enriched genes expressed in HSCLT and 
GM lineage-committed cells. (B) GO analyses of the gene signatures shown in (A). (C) GO 
analyses of the PC components shown in Figure 4B. (D) Heat map showing normalized dye 
intensity for expression of key hematopoietic markers (markers) and transcription factors (TFs) 
in the indicated populations. 
  
  
Figure S4, Hierarchy of lineage-biased MPPs, related to Figure 5. (A) Differentiation in 
vitro. Representative FACS plots showing kinetics of MPP2, MPP3 and MPP4 differentiation 
under myeloid culture conditions. Results are representative of 2 independent experiments. (B) 
Representative FACS plots and size of the indicated stem and progenitor populations in the BM 
and blood of Mpl+/+ and Mpl-/- littermates (3 mice/group). (C) Differentiation in vivo. 
Representative FACS plots of LSK and myeloid progenitor output 14 days following 
transplantation of 5,000 HSCLT, MPP2, MPP3 and MPP4 (3 mice/group). (D) Representative 
FACS plots (left) and quantification (right) of donor-derived myeloid and lymphoid BM output 
from the indicated populations 10 and 14 days after transplantation (3-5 mice/group). Results are 
mean ± SD. °p < 0.05, *p < 0.001. 
  
  
Figure S5, Molecular regulation at steady state, related to Figures 5 and 6. (A) Fluidigm 
gene expression analyses of surface markers. Results are expressed as mean (bar) and individual 
fold differences compared to HSCLT (8-12 pools of 100 cells/). (B) GFP expression in the 
indicated BM LSK subsets of Bmi1-eGfp and Pu.1-eYfp reporter mice. (C) Fluidigm gene 
expression analyses of cell cycle and DNA repair genes. Results are expressed as in (A). (D) PC 
analysis (top) and loading association (bottom) of Fluidigm gene expression data acquired from 
single cells (30-58 cells/population). (E) Representative FACS plots showing myeloid and 
lymphoid output in transplanted recipients at 2 and 3 weeks post injection compared to steady 
state control (Ctrl) mice. °p < 0.05, •p < 0.01, *p < 0.001.   
  
Figure S6, Molecular regulation during regeneration, related to Figure 6. Fluidigm gene 
expression analyses of key lineage determinant and surface marker genes in regenerating HSCLT 
and newly produced MPP2, MPP3 and MPP4 at 2 and 3 weeks post-transplantation. Results are 
expressed as mean (bar) and individual fold differences compared to their respective steady state 
control (Ctrl) populations (8-12 pools of 100 cells/population). °p < 0.05, • p < 0.01, *p < 0.001.   
  
Figure S7, Regenerating hematopoiesis, related to Figure 7. (A) Representative FACS plots 
of CD45.2 donor chimerism in secondary recipients transplanted with 2 and 3 weeks 
regenerating HSCLT and control (Ctrl) HSCLT. (B) LDA experimental scheme (top) and detailed 
results at 8 weeks post-transplantation (bottom). Lethally irradiated CD45.1 recipients were 
transplanted with various doses of BM cells obtained either from mice transplanted with donor 
CD45.2 HSCLT and re-isolated 2 weeks after transplantation (2wks BM; 50% chimerism) or 
from steady state control CD45.2 mice and mixed 1:1 with BM cells isolated from CD45.1 
recipient 2 weeks after sub-lethal irradiation (Ctrl BM; 50:50 mix). Transplanted mice were bled 
every month and analyzed for engraftment and donor chimerism. Mice with ≥ 0.5% donor PB 
chimerism at 8 weeks post-transplantation were considered engrafted. (C) Methylcellulose 
clonogenic assays of 4 weeks regenerating HSCLT, MPP2, MPP3 and MPP4. Ctrl are the same as 
in Figure 6D. Results are expressed as mean ± SEM (n = 1-4). (D) Engraftment over time of 4 
 week regenerative HSCLT in PB. Ctrl are the same as in Figure 7B. Results are expressed as 
mean ± SD (5-13 mice/group). (E) IL-1 and IL-6 levels in PB serum. Results are expressed as 
mean ± SD (9-12 mice/group). 
Table S1, Gene signatures and GO analysis of HSCLT and GM lineage-committed 
populations, related to Figure 4. List of top 1000 most highly expressed genes in each 
population relative to the indicated reference populations, ranked based on SAM score. p- and q-
values for the 1000th probe in each signature are displayed at the top of the list. GO categories 
are listed with accession number, enrichment p-value, and genes contributing to the enrichment. 
The highlighted GO categories are shown in Figure S3A. 
Table S2, GO analysis of genes driving PC separation, related to Figure 4. Complete list of 
GO categories enriched in the top 1000 genes driving each principal component. The table 
displays accession number, enrichment p-value, and genes contributing to the enrichment. The 
highlighted GO categories are shown in Figure S3C. 
Table S3, Gene signatures and GO analysis of MPP2, MPP3 and MPP4, related to Figure 
4. List of top 1000 most highly expressed genes in each population relative to the indicated 
reference populations, ranked based on SAM score. p- and q-values for the 1000th probe in each 
signature are displayed at the top of the list. GO categories are listed with accession number, 
enrichment p-value, and genes contributing to the enrichment. The highlighted GO categories are 
shown in Figure 4D. 
Table S4, Overlap with published MPP gene expression datasets, related to Figure 4. 
Complete list of genes overlapping between the 1000 most highly expressed genes in MPP2, 
MPP3 and MPP4, and published microarray datasets. Genes are ranked based on SAM score. 
Dataset accessions are GSE55525, GSE15907 or as described (Cabezas-Wallscheid et al., 2014). 
 Supplemental Experimental Procedures  
Mice 
Six- to 8-week-old CD45.2 C57Bl/6 wild type or β-actin-Gfp (Forsberg et al., 2006) mice were 
used as donor for cell isolation, and 8-12 week old CD45.1 C57Bl/6-Boy/J wild type mice as 
recipients for cell transplantation. Transplanted mice were kept on antibiotic-containing water for 
4 weeks. Bmi1-Gfp (Hosen et al., 2007), Pu.1-eYFP (Kirstetter et al., 2006) and Mpl-/- (Gurney et 
al., 1994) mice were used for hematopoietic analyses. Respective littermates were used as 
controls. All mice were maintained at UCSF in accordance with IACUC approved protocols. 
Flow cytometry 
Staining and enrichment procedures for stem and progenitor cells were performed as previously 
described (Santaguida et al., 2009; Reynaud et al., 2011). Briefly, unfractionationed or c-Kit-
enriched BM cells or splenocytes were stained with unconjugated rat anti-lineage (B220, CD3, 
CD4, CD5, CD8, Ter119, Mac-1, Gr-1, IL-7Ra) antibodies followed by goat anti-rat-Cy5PE or 
Qdot605 secondary antibodies. Cells were then stained with directly conjugated c-Kit-APC-
eFluor780, Sca-1-PB, Flk2-bio/streptavidin-Cy7PE, CD48-A647, CD150-PE, CD34-FITC and 
FcγR-PerCP-eFluor710 antibodies. For particular myeloid progenitor analyses (Pronk et al., 
2007), unfractionationed BM cells were stained with unconjugated rat anti-lineage antibodies 
followed by goat anti-rat-Cy5PE antibodies and directly conjugated c-Kit-APC-eFluor780, Sca-
1-PB, CD150-APC, CD41-PE, CD105-FITC and FcγR-PerCP-eFluor710 antibodies. For 
additional surface marker analyses, unfractionated BM cells were stained for lineage markers as 
above and subsequently stained with directly conjugated c-Kit-APC-eFluor780, Sca-1-PB, Flk2-
bio/streptavidin-Cy7PE, CD48-A647, CD150-PE (LSK populations) or c-Kit-APC-eFluor780, 
Sca-1-PB, CD34-Bio/streptavidin-Cy7PE and FcγR-PerCP-eFluor710 (myeloid progenitors) plus 
ESAM-FITC or CD41-FITC. Blood and BM mature cells were stained with directly conjugated 
B220-APC-A750, Gr-1-PB, Mac-1-Cy7PE, CD3-APC and Ter-119-Cy5PE antibodies 
supplemented with CD45.2-FITC and CD45.1-PE antibodies for transplantation studies. For 
analysis of donor-derived stem and progenitor populations in transplanted mice, unfractionated 
BM cells were stained for lineage markers as above and subsequently stained with directly 
conjugated c-Kit-APC-eFluor780, Sca-1-PB, Flk2-bio/streptavidin-Qdot605, CD48-A647, 
CD150-PE (LSK populations) or c-Kit-APC-eFluor780, Sca-1-PB, CD34-Bio/streptavidin-Qdot 
605 and FcγR-PerCP-eFluor710 (myeloid progenitors), plus CD45.2-FITC and CD45.1-Cy7PE 
antibodies. Cells were sorted on a FACS ARIAII and analyzed on an LSRII (Becton Dickinson) 
upon PI exclusion of dead cells. Each population was double sorted to ensure maximum purity.  
In vitro assays 
For expansion in liquid culture, cells (500 cells/well in 96-well plates) were grown in IMDM 
(Invitrogen) supplemented with 5% FBS (StemCell Technology), L-glutamine (2 mM), penicillin 
(50 U/ml)/streptomycin (50 µg/ml) and the following cytokines (all from PeproTech): SCF (25 
ng/ml), Flt3L (25 ng/ml), IL-11 (25 ng/ml), IL-3 (10 ng/ml), GM-CSF (10 ng/ml), TPO (25 
ng/ml) and EPO (4 U/ml). Cell numbers were determined by trypan blue exclusion of dead cells 
using a hematocytometer. For BrdU incorporation experiments, cells (5x103 to 104 cells/well in 
 96-well plates) were cultured for 1 hour in the presence of 60 µM BrdU (Sigma), fixed in 
PBS/4% paraformaldehyde and permeabilized in PBS/0.2% Triton-X100. After DNAse I 
treatment, cells were incubated with FITC-conjugated anti-BrdU antibody (Pharmingen), washed 
and resuspended in PBS/0.2% for analysis as described (Santaguida et al., 2009). For 
methylcellulose assays, cells (1 cell/100 µl/well in 96-well plates or 100 cells/1 ml in 3 cm dish) 
were cultured in M3231 methylcellulose (Stem Cell Technologies) supplemented as for the 
liquid cultures. Colonies were counted after 10 days of culture, and for the clonogenic assays at 
least 60 wells were monitored per cell type for each experiment. For MegaCult assays, cells 
(250-1x103 cells/1 ml in 3 cm dish) were plated and grown for 5 days in collagen-based media 
(StemCell Technologies) supplemented with TPO (50 ng/ml), IL-6 (20 ng/ml), IL-11 (50 ng/ml) 
and IL-3 (10 ng/ml). After fixation, Meg colonies were revealed by immunohistochemistry using 
an anti-CD41 antibody and scored upon visual inspection. For myeloid differentiation and 
surface marker analyses, cells (1,000 to 3,000 cells/well in 96-well plates) grown in StemPro 
media (Life Technologies) supplemented with penicillin (50 U/ml)/streptomycin (50 µg/ml), 
SCF (25 ng/ml), IL-11 (25 ng/ml), Flt3L (25 ng/ml), IL-3 (10 ng/ml) and GM-CSF (10 ng/ml). 
Cells were analyzed after different culture periods by flow cytometry using c-Kit-APC-A750, 
Sca-1-PB, CD150-PE, CD48-APC, Mac-1-FITC and FcγR-Cy5.5PE antibodies. For lymphoid 
differentiation assays, cells (1 to 500 cells/well in 96-well plates) were sorted into wells pre-
seeded with 5x105 OP9 (B cells) and OP9-DL1 (T cells) stromal cells as previously described 
(Reynaud et al., 2008). For B cell differentiation, cells were cultured in OptiMEM (Invitrogen) 
supplemented with 5% FBS in presence of SCF (10 ng/ml), Flt3L (10 ng/ml) and IL-7 (5 ng/ml). 
After sequential withdrawal of Flt3L and SCF, cells were maintained with IL-7 and analyzed 
after different culture periods by flow cytometry using CD19-PB and Mac-1-APC antibodies. 
For T cell differentiation, cells were cultured in OptiMEM supplemented with 5% FBS in 
presence Flt3L (10 ng/ml) and IL-7 (5 ng/ml), and analyzed by flow cytometry using CD25 
biotin/Streptavidin-Cy7PE and CD44-APC antibodies. 
In vivo assays  
Transplantations and lineage tracking experiments were performed as previously described 
(Forsberg et al., 2006; Reynaud et al., 2011). Congenic recipient mice (CD45.1) were either 
lethally (1100 rad, split dose 3h apart) or sub-lethally (950 rad, split dose 3h apart) irradiated 
using a cesium source. Purified donor cells were injected into the retro-orbital plexus and 
hematopoietic reconstitution was monitored over time in the peripheral blood based on CD45.2 
or GFP expression. For sub-lethal irradiation, purified donor cells alone were injected and 
transplanted mice were first bled after 7 days and then every 3-5 days for up to 34 days. For 
lethal irradiation, unfractionated donor BM cells alone, or purified donor cells together with 
300,000 Sca-1-depleted congenic helper BM cells, were injected and transplanted mice were first 
bled after 4 weeks and then on a monthly schedule. Peripheral blood was obtained from retro-
orbital bleeding, and either collected in 4 ml of ACK (150 mM NH4Cl/10 mM KHCO3) 
containing 10 mM EDTA for flow cytometry analyses, or in EDTA-coated Microtainer tubes 
(Beckton-Dickenson) for complete blood counts using an Hemavet hematology system (Drew 
Scientific). Results of limit dilution analyses (LDA) were calculated with the ELDA software 
(http://bioinf.wehi.edu.au/software/elda/). Spleen colony-forming unit (CFU-S) assays were 
performed as described (Forsberg et al., 2006). Lethally irradiated recipient mice were 
transplanted with 50 to 250 cells of the indicated populations. Spleens were harvested 12 days 
 after transplantation and fixed in Tellyesniczky’s solution to determine CFU-S12 frequency 
(numbers of injected cells divided by numbers of observed spleen colonies). For EdU 
incorporation experiments, mice were injected with 10 mM EdU (Life Technologies) 1h prior 
harvest. Purified cells were pipetted onto poly-lysine coated slides (500-2,000 cells per slide) and 
EdU incorporation was detected using A594-labeled azide click chemistry according to the 
manufacturer’s instruction (Life Technologies). For Wright-Giemsa staining, purified cells were 
cytospun onto glass slides (1,000-5,000 cells per slide) and processed according to standard 
protocols.  
Cytokine analyses  
For PB serum, blood was harvested from euthanized mice via cardiac puncture, allowed to 
coagulate at room temperature for 30 min, and subsequently spun down at 12,000 × g for 10 min 
to remove blood cells. For BM fluid, the four long bones (two femurs and two tibiae) of the same 
mice were flushed with 150-200 µl HBSS/2% FBS using a 0.3cc insulin syringe with a 28g 
needle and spun at 500 × g for 5 min to remove BM cells. Supernatants were further clarified by 
spinning down at 12,000 × g for 10 min, and samples were subsequently stored at -20°C until 
use. For cytokine measurement, 50 µl of 2x-diluted sample was analyzed with a Luminex 
Cytokine Mouse 20-plex panel (Life Technologies) using a BioPlex instrument (Bio-Rad) 
according to the manufacturer’s instructions. 
Microarray analyses 
For microarray analyses, three to five independent biological replicates were used for each 
population. Total RNA was isolated from 2x104 purified cells directly sorted into TRIzol-LS 
(Invitrogen) and purified using Arcturus PicoPure (Applied Biosystems) with RNase-free DNase 
(Qiagen). RNA was amplified, labeled, and fragmented using NuGEN Ovation Pico linear 
amplification kits (Nugen Technologies) and hybridized onto mouse Gene ST 1.0 arrays 
(Affymetrix). Gene signatures were determined by contrasting the gene expression patterns 
characteristic of each population (MPP2, MPP3, MPP4, HSCLT and GM lineage-committed 
cells) against the other indicated population(s). Gene expression microarray data were 
normalized using RMA followed by quantile normalization as implemented in the 2.15.1 R 
package (www.r-project.org) using a standard (lambda=1) exponential reference distribution. For 
a specific population a dichotomous division of the samples was defined by labeling the 
population (e.g., MPP3) as the first class and the other two populations (e.g., MPP2 and MPP4) 
as the second class. Significance Analysis of Microarrays (SAM) (Tusher et al., 2001) was then 
performed using the expression data and the dichotomous labeling of the data to determine SAM 
delta scores, which reflect the degree of differential expression of each gene in the first class 
compared to the second. SAM performs a robust version of a two-way test that safeguards the 
analysis against extremely low variance estimates associated with genes of low expression. The 
top 1000 most highly expressed genes were collected as the gene signature for each population. 
Reported p- and q-values for the 1000th probe in each gene signature were derived via modified 
t-test and false discovery rate (FDR) with 100 label permutations (Storey and Tibshirani, 2003). 
Microarray data were clustered by Pearson correlation with complete linkage using 
MultiExperiment Viewer 4.5.1. PC analysis of microarray data was performed using the prcomp 
function in R. Functional pathways representative of each gene signature were analyzed for 
 enrichment in gene categories from the Gene Ontology (GO) database (Gene Ontology 
Consortium, 2010) using DAVID Bioinformatics Resources ver. 6.7 (Huang et al., 2009). For 
gene signature and each GO category, the significance of the number of overlapping genes in the 
two sets was calculated using a Fisher's Exact test performed by the DAVID software. The P-
value resulting from the test reflects the probability of obtaining the observed overlap or greater 
by chance. The –log10 of the P-value provides an intuitive level of significance and was used to 
rank GO categories. For principal component analysis the loadings of the centroids for each cell 
population in the first three principal components were used to generate plots. GO analyses of 
were conducted using DAVID on the top 1000 genes contributing to each of the three principal 
components in its positive direction. Comparisons with MPP gene signatures from previously 
published microarray data were conducted either by running an independent SAM analysis on 
the published dataset to identify differentially expressed genes (Beerman et al., 2014) or, when 
fewer than three biological replicates were present per population (Gazit et al., 2013), differential 
expression was determined by subtracting one gene vector from the other. The top 1000 up or 
downregulated genes present in both datasets were then identified and overlapped with the gene 
signatures of MPP2, MPP3 and MPP4 described above. For RNAseq data (Cabezas-Wallscheid 
et al., 2014), differential expression results generated in this study were directly compared 
against the MPP2, MPP3 and MPP4 gene signatures described above. 
Fluidigm analyses 
Gene expression analyses using the Fluidigm 96.96 Dynamic Array IFC were performed as 
previously described (Reynaud et al., 2011). Briefly, pools of 100 cells or single cells were 
sorted directly into CellsDirect resuspension buffer (Invitrogen), reverse-transcribed and 
preamplified for 18 (bulk) or 22 cycles (single cells) using Superscript III Platinum Taq DNA 
polymerase (Invitrogen) using proprietary target-specific primers (Fluidigm). The resulting 
cDNAs were analyzed on a Biomark system (Fluidigm) using EvaGreen Sybr dye (Bio-Rad). 
Data were collected using Biomark Data Collection Software (Fluidigm). For bulk populations, 
data were analyzed using Biomark qPCR analysis software (Fluidigm) with a quality threshold 
of 0.65 and linear baseline correction, and identical settings used across all experiments 
performed on different 96.96 dynamic arrays. Melt curves and Tm values for each assay reaction 
were checked individually, and reactions with melt curves showing multiple peaks or poor 
quality (<0.65) were discarded, leaving 57 genes, excluding housekeeping genes (Gapdh, Hprt, 
Tubb5 and Gusb) for further analysis. For gene expression quantification, data were exported as 
an Excel .csv file and analyzed by the ΔΔCt method using Gusb for normalization as previously 
described (Reynaud et al., 2011). For PC analysis on bulk populations, data were subjected to 
quality control as described above and normalized to Gapdh. Housekeeping genes were removed 
prior to analysis, and genes with expression values above the range of the instrument (Ct > 28) 
were set to 29. PC analysis was then conducted using the prcomp function in R. For single cell 
gene expression analysis, 5 negative control wells (no cell sorted), 3 positive control wells (20 
cells) and 88 wells containing a single cell were sorted for each population, corresponding to a 
single 96.96 dynamic array. Single-cell data were initially analyzed using Biomark qPCR 
analysis software as above. Of the 57 genes, those showing poor Tm quality in one or more 
reactions were removed from analysis, leaving 49 genes for further analysis (excluding 
housekeeping genes). Cells expressing fewer than 29 genes (poor quality) were also excluded, 
leaving 196 cells (40 HSCLT, 45 MPP2, 41 MPP3, 70 MPP4) for further analysis. Expression 
 levels of Gapdh were used for normalization and PC analysis was conducted as above. tSNE 
analysis was performed using the MATLAB implementation (http://homepage.tudelft.nl/19j49/t-
SNE.html) with standard settings (van der Maaten and Hinton, 2008). Data were preprocessed to 
keep only the first 28 components of PCA containing 95% of the information. Discriminant 
analysis classification was performed in Matlab using a quadratic classification. 
Statistics 
All the data are expressed as mean ± standard deviation (SD) or standard error of the mean 
(SEM) as indicated. P values were generated using unpaired Student’s t-test or a Mann-Whitney 
u-test (Fluidigm), and considered significant when ≤ 0.05. N indicates the numbers of 
independent experiments performed.   
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